Omeros Corporation - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

Omeros Corporation - Product Pipeline Review - 2016

Omeros Corporation - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
Omeros Corporation - Product Pipeline Review - 2016
Published Aug 10, 2016
115 pages — Published Aug 10, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Omeros Corporation - Product Pipeline Review - 2016, provides an overview of the Omeros Corporations pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Omeros Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Omeros Corporation
- The report provides overview of Omeros Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Omeros Corporations pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Omeros Corporations out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Omeros Corporations strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Omeros Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Omeros Corporations pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  
Source:
Document ID
GMDHC08113CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables91
  List of Figures91
Omeros Corporation Snapshot101
  Omeros Corporation Overview101
  Key Information101
  Key Facts101
Omeros Corporation Research and Development Overview117
  Key Therapeutic Areas117
Omeros Corporation Pipeline Review182
  Pipeline Products by Stage of Development181
  Pipeline Products Monotherapy191
Omeros Corporation Pipeline Products Glance206
  Omeros Corporation Late Stage Pipeline Products201
    Phase III Products/Combination Treatment Modalities201
  Omeros Corporation Clinical Stage Pipeline Products211
    Phase II Products/Combination Treatment Modalities211
  Omeros Corporation Early Stage Pipeline Products221
    Preclinical Products/Combination Treatment Modalities223
    Discovery Products/Combination Treatment Modalities251
Omeros Corporation Drug Profiles2669
  OMS-721261
    Product Description261
    Mechanism of Action261
    R&D Progress262
  OMS-405281
    Product Description281
    Mechanism of Action281
    R&D Progress281
  OMS-824291
    Product Description291
    Mechanism of Action291
    R&D Progress291
  Monoclonal Antibodies for Oncology, Metabolic, Cardiovascular and Musculoskeletal Disorders301
    Product Description301
    Mechanism of Action301
    R&D Progress302
  Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications321
    Product Description321
    Mechanism of Action321
    R&D Progress322
  OMS-527341
    Product Description341
    Mechanism of Action341
    R&D Progress342
  OMS-616361
    Product Description361
    Mechanism of Action361
    R&D Progress362
  OMS-906381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  Small Molecule to Agonize GPR52 for Schizophrenia391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  Small Molecule to Agonize PTH-1R for Osteoporosis401
    Product Description401
    Mechanism of Action401
    R&D Progress401
  Small Molecule to Antagonize GPR101 for Appetite Disorders411
    Product Description411
    Mechanism of Action411
    R&D Progress411
  Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  Small Molecule to Antagonize GPR139 for Motor Disorders431
    Product Description431
    Mechanism of Action431
    R&D Progress431
  Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy441
    Product Description441
    Mechanism of Action441
    R&D Progress441
  Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  Small Molecule to Antagonize GPR17 for Central Nervous System Disorders461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia471
    Product Description471
    Mechanism of Action471
    R&D Progress471
  Small Molecule to Antagonize GPR182 for Pancreatic Cancer481
    Product Description481
    Mechanism of Action481
    R&D Progress481
  Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer491
    Product Description491
    Mechanism of Action491
    R&D Progress491
  Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  Small Molecule to Antagonize GPR27 for Obesity, Diabetes and Schizophrenia511
    Product Description511
    Mechanism of Action511
    R&D Progress511
  Small Molecule to Antagonize GPR31 for Anxiety Disorders521
    Product Description521
    Mechanism of Action521
    R&D Progress521
  Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes531
    Product Description531
    Mechanism of Action531
    R&D Progress531
  Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  Small Molecule to Antagonize GPR87 for Oncology561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  Small Molecule to Antagonize NMUR2 for Pain571
    Product Description571
    Mechanism of Action571
    R&D Progress572
  Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders591
    Product Description591
    Mechanism of Action591
    R&D Progress591
  Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia and Lymphoma601
    Product Description601
    Mechanism of Action601
    R&D Progress601
  Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders611
    Product Description611
    Mechanism of Action611
    R&D Progress611
  Small Molecule to Target GPR132 for Cardiovascular Diseases621
    Product Description621
    Mechanism of Action621
    R&D Progress621
  Small Molecule to Target GPR135631
    Product Description631
    Mechanism of Action631
    R&D Progress631
  Small Molecule to Target GPR141 for Respiratory and Immune Disorders641
    Product Description641
    Mechanism of Action641
    R&D Progress641
  Small Molecule to Target GPR150 for Ovarian Cancer651
    Product Description651
    Mechanism of Action651
    R&D Progress651
  Small Molecule to Target GPR151 for CNS Diseases661
    Product Description661
    Mechanism of Action661
    R&D Progress661
  Small Molecule to Target GPR153 for Schizophrenia671
    Product Description671
    Mechanism of Action671
    R&D Progress671
  Small Molecule to Target GPR162 for Neuropsychiatric Disorders681
    Product Description681
    Mechanism of Action681
    R&D Progress681
  Small Molecule to Target GPR171 for Eating and Hematological Disorders691
    Product Description691
    Mechanism of Action691
    R&D Progress691
  Small Molecule to Target GPR174 for Immunology, Neurology and Oncology701
    Product Description701
    Mechanism of Action701
    R&D Progress701
  Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections711
    Product Description711
    Mechanism of Action711
    R&D Progress711
  Small Molecule to Target GPR21 for Obesity and Diabetes721
    Product Description721
    Mechanism of Action721
    R&D Progress721
  Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis731
    Product Description731
    Mechanism of Action731
    R&D Progress731
  Small Molecule to Target GPR25 for Arterial Stiffness741
    Product Description741
    Mechanism of Action741
    R&D Progress741
  Small Molecule to Target GPR32 for Acute Inflammation751
    Product Description751
    Mechanism of Action751
    R&D Progress751
  Small Molecule to Target GPR37 for Parkinson's Disease761
    Product Description761
    Mechanism of Action761
    R&D Progress761
  Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy771
    Product Description771
    Mechanism of Action771
    R&D Progress771
  Small Molecule to Target GPR45781
    Product Description781
    Mechanism of Action781
    R&D Progress781
  Small Molecule to Target GPR50 for CNS and Metabolic Disorders791
    Product Description791
    Mechanism of Action791
    R&D Progress791
  Small Molecule to Target GPR63 for Autism801
    Product Description801
    Mechanism of Action801
    R&D Progress801
  Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders811
    Product Description811
    Mechanism of Action811
    R&D Progress811
  Small Molecule to Target GPR80 for Hepatocellular Carcinoma821
    Product Description821
    Mechanism of Action821
    R&D Progress821
  Small Molecule to Target GPR82 for Appetite Disorders and Body Weight831
    Product Description831
    Mechanism of Action831
    R&D Progress831
  Small Molecule to Target GPR83 for CNS and Immunological Disorders841
    Product Description841
    Mechanism of Action841
    R&D Progress841
  Small Molecule to Target LGR4 for Oncology and Osteoporosis851
    Product Description851
    Mechanism of Action851
    R&D Progress851
  Small Molecule to Target LGR5 for Esophageal Adenocarcinoma861
    Product Description861
    Mechanism of Action861
    R&D Progress861
  Small Molecule to Target LGR6 for Dermatology871
    Product Description871
    Mechanism of Action871
    R&D Progress871
  Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer881
    Product Description881
    Mechanism of Action881
    R&D Progress881
  Small Molecule to Target MRGE for Pain891

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Omeros Corporation - Product Pipeline Review - 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Omeros-Corporation-Product-Pipeline-Review-2016-2088-16367>
  
APA:
Global Markets Direct - Market Research. (2016). Omeros Corporation - Product Pipeline Review - 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Omeros-Corporation-Product-Pipeline-Review-2016-2088-16367>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.